Objectives: The objective of this study was to assess the relationship of VEGF-C and LVD with pathoclinical factors of potential prognostic value and with the survival time of gastric cancer patients. Materials and methods: A total of 103 radically operated patients for gastric cancer who did not undergo neoadjuvant therapy were included in this study. The minimum follow-up period after surgery was 61 months. VEGF-C and lymphatic vessels were immunohistochemically determined using antibodies, including VEGF-C (c-20) sc 1881-Goat Polyclonal IgG (Santa Cruz Biotechnology) and Podoplanin D2-40 Mouse Monoclonal Antibody (ROCHE). The relationship between VEGF-C expression in gastric adenocarcinoma cells and the density of lymphatic vessels at the periphery of the primary tumor was assessed, along with the relationships of VEGF-C and LVD with selected pathoclinical parameters of gastric cancer and prognosis. Results: VEGF-C overexpression was associated with increased LVD (Mann–Whitney U test,p= 0.03) and the Lauren intestinal type of cancer (Pearson’s chi-square test,p< 0.001). Increased LVD was more often associated with cancers located beyond the cardia (Mann–Whitney U test,p= 0.04). We did not demonstrate an association of VEGF-C or LVD with OS or with prognostic features, such as pT, pN, or pTNM staging. However, in the Lauren intestinal type of cancer, VEGF-C overexpression correlated with shorter OS (log-rank,p= 0.01) and, at the level ofp= 0.05 in multivariate analysis, it had an independent negative prognostic value. Conclusions: Peritumoral overexpression of VEGF-C in primary gastric cancer tumors is associated with increased LVD. The Lauren intestinal type of cancer is associated with VEGF-C overexpression. The overexpression of VEGF-C in intestinal-type gastric cancer is associated with worse prognosis.
目的：本研究旨在评估血管内皮生长因子C（VEGF-C）与淋巴管密度（LVD）同潜在预后价值的病理临床因素以及胃癌患者生存时间之间的关系。材料与方法：本研究共纳入103例接受根治性手术且未接受新辅助治疗的胃癌患者。术后最短随访期为61个月。采用免疫组化方法检测VEGF-C及淋巴管，所用抗体包括VEGF-C（c-20）sc 1881-山羊多克隆IgG（圣克鲁斯生物技术公司）和Podoplanin D2-40小鼠单克隆抗体（罗氏公司）。评估了胃腺癌细胞中VEGF-C表达与原发肿瘤周边淋巴管密度的关系，以及VEGF-C和LVD与胃癌特定病理临床参数及预后的关联。结果：VEGF-C过表达与LVD增加（Mann-Whitney U检验，p=0.03）及Lauren肠型胃癌（皮尔逊卡方检验，p<0.001）相关。LVD增加更常见于贲门以外部位的癌症（Mann-Whitney U检验，p=0.04）。未发现VEGF-C或LVD与总生存期（OS）或pT、pN、pTNM分期等预后特征存在关联。然而，在Lauren肠型胃癌中，VEGF-C过表达与较短OS相关（时序检验，p=0.01），在多变量分析中达到p=0.05水平，具有独立的负面预后价值。结论：原发性胃癌肿瘤周边VEGF-C的过表达与LVD增加相关。Lauren肠型胃癌与VEGF-C过表达相关。肠型胃癌中VEGF-C的过表达与不良预后相关。
肿瘤(癌症)患者之家